MAPLE GROVE, Minn.
, June 4, 2014
/PRNewswire/ -- Upsher-Smith Laboratories, Inc
., today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Vogelxo (testosterone) gel for topical use CIII. The company is preparing to launch Vogelxo in the near future.
Upsher-Smith Laboratories, Inc., founded in 1919, is a growing pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy. Improving Life. With capabilities ranging from early-stage research to delivering on-market products, Upsher-Smith is committed to offering quality products that enable people to live life to its greatest potential. Upsher-Smith's approach to product development and partnering has resulted in a broad range of both branded and generic therapeutic solutions to address patients' needs. The Company has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders, and has a robust pipeline of promising CNS compounds in various stages of development. For more information, visit www.upsher-smith.com.
Please see Full Prescribing Information, including Boxed Warning, at http://tinyurl.com/mc7baos.
Logo - http://photos.prnewswire.com/prnh/20130520/NY17281LOGO
SOURCE Upsher-Smith Laboratories, Inc.